Narendra Kumar

Narendra Kumar

Auto-generated profile, based on publicly available information

Narendra Kumar

Department of Radiotherapy and Oncology, PGIMER, Chandigarh, India

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2012 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
NKNarendra Kumar
Narendra Kumar
RKRitesh Kumar
Ritesh Kumar
RKRAKESH KAPOOR
RAKESH KAPOOR
SGSushmita Ghoshal
Sushmita Ghoshal
PKPramod Kumar
Pramod Kumar
SSSuresh Chander Sharma
Suresh Chander Sharma

26 April 2011 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
PSPravin Shashikant Salunke
Pravin Shashikant Salunke
KGKirti Gupta
Kirti Gupta
VMVinod Malik
Vinod Malik
NKNarendra Kumar
Narendra Kumar
LHLauren E. Henke
Lauren E. Henke
JPJohn D. Pfeifer
John D. Pfeifer

1 January 2018 in Surgical Neurology International
Verified
Journal Article
Open access
BRBishan Dass Radotra
Bishan Dass Radotra
DCDebajyoti Chatterjee
Debajyoti Chatterjee
NKNarendra Kumar
Narendra Kumar
RVRakeshKumar Vasishta
RakeshKumar Vasishta
SGSunilKumar Gupta
SunilKumar Gupta
According to the current World Health Organization (WHO) classification of central nervous system (CNS) tumors (2016), histological diagnosis of gliomas should be supplemented by molecular information. This study was carried out to determine the frequency of isocitrate dehydrogenase 1 (IDH1), ATRX, and BRAF V600E mutations in different grade astrocytomas and their prognostic value. Eighty cases of astrocytoma (15 pilocytic astrocytoma, 25 diffuse astrocytoma, 15 anaplastic astrocytoma, and 25 glioblastoma) with follow-up information were analyzed using immunohistochemistry for IDH1 mutant protein, ATRX, p53, and BRAF. Sanger sequencing was carried out for IDH1 exon 4 and BRAF exon 15. All pilocytic astrocytoma and primary glioblastoma cases were negative for IDH1 mutation. IDH1 mutation was detected in 80% (20/25) DA and 87% (13/15) AA cases. IDH1 R132H was the commonest IDH1 mutation (94.1%) and immunohistochemistry showed 100% sensitivity and specificity to detect this mutation. Loss of nuclear ATRX expression was found in 87% (20/23) and 100% (14/14) DA and AA cases, respectively. IDH1 mutant DA patients had longer overall survival than IDH1 wild cases, although this difference was not significant (79.5 months vs. 42.5 months, P value 0.417). BRAF V600E mutation was not detected in any astrocytic tumor. IDH1 and ATRX mutations are very common in diffuse astrocytoma and anaplastic astrocytoma, while they are rare in pilocytic astrocytoma and glioblastoma. Immunohistochemistry for IDH1 and ATRX can successfully characterize the diffuse gliomas into molecularly defined groups in majority of the cases. BRAF V600E mutation is rare in astrocytic tumors in Indian population.

1 December 2013 in Journal of Neurosciences in Rural Practice
Verified
Journal Article
Open access
PDF file
NKNarendra Kumar
Narendra Kumar
PKPankaj Kumar
Pankaj Kumar
SAShabab Lalit Angurana
Shabab Lalit Angurana
DKDivya Khosla
Divya Khosla
KMKanchan Kumar Mukherjee
Kanchan Kumar Mukherjee
SSSuresh Chander Sharma
Suresh Chander Sharma
Aims: We present retrospective analysis of patients of glioblastoma multiforme (GBM) and discuss clinical characteristics, various treatment protocols, survival outcomes, and prognostic factors influencing survival. Materials and Methods: From January 2002 to June 2009, 439 patients of GBM were registered in our department. The median age of patients was 50 years, 66.1% were males, and 75% underwent complete or near-total excision. We evaluated those 360 patients who received radiotherapy (RT). Radiotherapy schedule was selected depending upon pre-RT Karnofsky Performance Status (KPS). Patients with KPS < 70 (Group I, n = 48) were planned for RT dose of 30-35 Gy in 10-15 fractions, and patients with KPS ≥ 70 (Group II, n = 312) were planned for 60 Gy in 30 fractions. In group I, six patients and in group II, 89 patients received some form of chemotherapy (lomustine or temozolomide). Statistical Analysis Used: Statistical analysis was done using Statistical Package for Social Sciences, version 12.0. Overall survival (OS) was calculated using Kaplan-Meier method, and prognostic factors were determined by log rank test. The Cox proportional hazards model was used for multivariate analysis. Results: The median follow-up was 7.53 months. The median and 2-year survival rates were 6.33 months and 2.24% for group I and 7.97 months and 8.21% for group II patients, respectively ( P = 0.001). In multivariate analysis, site of tumor (central vs. others; P = 0.006), location of tumor (parietal lobe vs. others; P = 0.003), RT dose (<60 Gy vs. 60 Gy; P = 0.0001), and use of some form of chemotherapy ( P = 0.0001) were independent prognostic factors for survival. Conclusions: In patients with GBM, OS and prognosis remains dismal. Whenever possible, we should use concurrent and/or adjuvant chemotherapy to maximize the benefits of post-operative radiotherapy. Patients with poor performance status may be considered for hypofractionated RT schedules, which have similar median survival rates as conventional RT.

1 March 2018 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
NKNarendra Kumar
Narendra Kumar
GSGulladamane Yogesh Srinivasa
Gulladamane Yogesh Srinivasa
RMRenu Madan
Renu Madan
PSPravin Salunke
Pravin Salunke

21 November 2012 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
RKRitesh Kumar
Ritesh Kumar
SGSushmita Ghoshal
Sushmita Ghoshal
DKDivya Khosla
Divya Khosla
SBShreekant Bharti
Shreekant Bharti
ADAshim Das
Ashim Das
SSSuresh Chander Sharma
Suresh Chander Sharma